Letters of neonatal hypoglycaemia. We therefore wish to discuss how such discrepancies can occur.
Their Fig. I shows that Leonard et al. found nearly one-third of their patients to be in the hypoglycaemic range for full-term infants «2mmol(L); as judged from the average of HemoCue plus the laboratory glucose values at the abscissa (their Beckman results must have been even lower). Since such a clinical situation is not very likely, the finding probably indicates some technical error within their laboratory reference procedure.
Leonard obtained blood from a heel prick and transferred it into fluoride oxalate tubes. Hemo-Cue readers were performed immediately by the bedside and the samples were then sent for reference measurement by the laboratory. A delay up to 1 h in the laboratory before analysis was accepted. Several papersv" describe the inability of fluoride to prevent glycolysis during the first 1-3 h after blood collection. Glucose loss in blood stored for 1 h at room temperature can be between 10-15% at normal glucose concentration and normal haematocrit (approximately O'5 mmol(L). The loss is largely independent of the blood glucose concentration because glucose uptake by the erythrocytes is constant. Glycolysis will be increased at elevated haematocrit.v" as occurs in many newborns. Hence, much of the discrepancy between the two methods used by Leonard et al., 
Author's reply
In his letter, Dr Raile indicates that true comparisons of glucose can only be made using protein precipitation, immediate analysis or storage on ice, I and has provided data from samples after protein precipitation with perchlorate. Our study was conducted to reflect routine clinical practice and, as such, I am not aware of any laboratory in the UK using perchlorate precipitation routinely for glucose analysis. It is common practice, however, to collect blood for glucose measurement into tubes containing fluoride oxalate as a preservative. Dr Raile quite rightly points out our failure to include the imprecision of our laboratory analyser. Our Beckman CX7 analyser shows between day coefficient of variation's (n = 20) of 2·8%, 1'5%, 1·6% at glucose values of 2'5,6'3, 13·7mmol(L. This is in accordance with analytical goals as defined by Fraser.?
We do agree with Dr Raile that a delay in treatment of a hypoglycaemic neonate is unacceptable but the cut-off glucose level for hypoglycaemia remains a problem to define. Sensitivity and specificity at a level of 3 mmol(L is given in our original article as we consider this to be a reasonable cut-off level.' If <2'Ommol(L is regarded as hypoglycaemic" then, in our case, the Hemocue detected seven babies with glucose less than or equal to 2'Ommol(L whilst the laboratory detected 27 cases. It is for this reason that we adhere to strict protocols for using Hemocue analysers on our special-care baby unit (SCBU), which incorporate daily quality control measurements, monthly inspection and agreed protocols for laboratory confirmation of hypoglycaemia ( < 5 mmol(L).
The cost of running Hemocue analysers on our unit may not be directly comparable to other units and was included to point out that there are significant running costs involved in nearpatient testing as well as the laboratory cost. In this respect, it would be interesting to see costing data from hospitals who have compared an airtube link from their SCBU to the laboratory with SCBU near patient testing facilities.
MAUREEN LEONARD
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Serum antioxidant activity after myocardial infarction
Miller et al. measured total antioxidant activity (TAA) and the 'antioxidant gap' after myocardial infarction. I They reported that whereas no significant changes were observed in serum total antioxidant activity, a decline in the 'antioxidant gap' after myocardial infarction was associated with a significantly higher mortality. We would like to comment on the validity of their method of derivation of the 'antioxidant gap'. To calculate the 'antioxidant gap', for each serum sample Miller et al. subtracted from TAA, the activity ascribable to albumin and uric acid. This involved measuring the serum concentrations of albumin and urate and multiplying these values by previously derived conversion factors of 0·69 per mmol/L for albumin and 1·0 per mmol/L for urate.?
The contribution made by albumin to TAA was also recently investigated in our laboratory using a Centrifree Micropartition System (Amicon) which retained proteins of molecular weight > 30 000. TAA was measured in serum samples before and after filtration. The albumin concentrations in serum samples pre and post-filtration were also measured. Furthermore, serial dilutions of albumin (Sigma) were prepared and analysed directly for antioxidant activity. Using both approaches, we calculated that the albumin contribution to the TAA was 0·90 per rnrnol/L, As such, our
Letters 333 results indicate that the conversion factor for albumin used by Miller et al. is an underestimate and that albumin or albumin complexes make a larger contribution to antioxidant activity than previously appreciated. It follows, therefore, that the calculation of the 'antioxidant gap' may be erroneous. Our results for uric acid were in agreement with the figure quoted by Miller et al. Furthermore, irrespective of the above potential discrepancy, it may be wholly inaccurate to assume that the in vivo antioxidative capacity of albumin remains constant at all times. Albumin is a major transport protein in the blood, and there occurs continuous fluctuations in the degree of binding of different compounds to its binding sites, e.g. during stress and in disease situations, all of which may alter its antioxidative capacity.
Therefore, we suggest that the discrepancy found between reported 1 and our experimental findings of the contribution from albumin/ albumin complexes to the total antioxidant activity needs to be investigated further, especially if the concept of antioxidant gap is to have any clinical value.
